Market cap
$1 Mln
Recently Viewed
Clear All$0.35
$-0.11
(-23.33%)
As on 16-Aug-2023 09:30EDT
Market cap
$1 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
6.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-10 Mln
ROE
-3.4 %
ROCE
-- %
Industry P/E
46.76
EV/EBITDA
-0.3
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,214,230
CFO
$-163.95 Mln
EBITDA
$-170.44 Mln
Net Profit
$-187.49 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
| -91.4 | -17.9 | -86.8 | -97.3 | -83.9 | -77.5 | -- |
|
BSE Sensex*
| -9.2 | 6.8 | -6.6 | -4.3 | 7.9 | 9.1 | 11.6 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
| -93.9 | 13.2 | -54.5 | -72.4 | 25.0 | -9.4 | -48.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
HTG Molecular Diagnostics (HTGM)
|
0.3 | 1.1 | 6.2 | -20.2 | -319.3 | -2394.9 | -- | 6.3 |
| 7.9 | 5,292.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 1.0 | |
| 299.5 | 8,082.3 | 2,583.2 | 759.9 | 25.2 | 10.8 | 10.8 | 1.1 | |
| 34.3 | 5,563.8 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.2 | |
| 117.0 | 7,074.2 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.8 | |
| 81.2 | 5,490.1 | 1,541.6 | 233.6 | 21.6 | 21.4 | 24.7 | 5.0 | |
| 178.5 | 9,353.6 | 1,526.9 | -151.5 | 20.0 | -17.1 | 46.8 | 13.0 | |
| 324.8 | 13,067.9 | 1,403.7 | 177.7 | 14.7 | 13.8 | 73.7 | 9.1 | |
| 113.1 | 6,632.6 | 738.3 | 48.9 | 11.4 | 2.4 | 136.7 | 3.2 | |
| 30.4 | 13,623.0 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.3 | 2.6 |
HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular... profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Pres, CEO & Director
Mr. John L. Lubniewski
Pres, CEO & Director
Mr. John L. Lubniewski
Headquarters
Tucson, AZ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of HTG Molecular Diagnostics Inc (HTGM) is $0.35 (NASDAQ) as of 16-Aug-2023 09:30 EDT. HTG Molecular Diagnostics Inc (HTGM) has given a return of -83.91% in the last 3 years.
Since, TTM earnings of HTG Molecular Diagnostics Inc (HTGM) is negative, P/E ratio is not available.
The P/B ratio of HTG Molecular Diagnostics Inc (HTGM) is 6.26 times as on 16-Aug-2023, a 93 premium to its peers’ median range of 3.24 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of HTG Molecular Diagnostics Inc (HTGM) are Rs -- and Rs -- as of 30-Apr-2026.
HTG Molecular Diagnostics Inc (HTGM) has a market capitalisation of $ 1 Mln as on 16-Aug-2023. As per SEBI classification, it is a company.
Before investing in HTG Molecular Diagnostics Inc (HTGM), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.